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Summarv
Purified PIVKA-II * exhibits some factor II (prothrombin) activity in the
one-stage coagulation assay and this factor II activity does not come from
residual amounts of factor II but originates from PIVKA-II itself. It is shown
that PIVKA-II is converted by a normal prothrombinase complex (factor V.
and factor X. adsorbed onto a phospholipid interface) more readily than by
phospholipids and factor X" alone. This suggests that binding between PIVKA-
II and factor V. is an essential feature in the formation of the enzyme'sub-
strate complex and from this we infer that a direct interaction between factor
V. and prothrombin plays a r6le in the prothrombinase'prothrombin com-
plex.
Introduction
Activated factor V is known to be an essential component of the prothrom-
binase complex 12,31. Although it has nb known enzymatic properties of its
own, it markedly accelerates the thrombin generation from factor II (pro-
thrombin) by activated factor X. This acceleration is even more pronounced
when the factors II, Vu and Xu are adsorbed to a phospholipid-water interface
[3]. Ca2* presumably bind to the 1-carboxy glutamic acid residues (7-carboxy-
Glu) of the factors II and X" and thereby favor the binding of these factors to
the phospholipids t4-61. Factor V. presumably binds to the phospholipidvia
ahydrophobic bond [7].
The mechanism of the accelerating role of factor V in the prothrombinase '
prothrombin complex is unknown. It has been shown that a part of the pro-
Abbreviation: SP-Sephadex, sulpho-propyl Sephadex.
* PMA-II. e decarboxy prothrombin. fu the protein analogous to prothrombin which is induced in
human and bovine plasma by vitamin K absence or coumarin treatment [1].
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thrombin molecule binds to factor V" [2].Possible roles of factor V are [8]:
(a) inducing favorable conformational changes in the active site-bearing protein
(factor X") and/or a similar role towards the substrate (factor II); (b) binding to
factor Xu and/or factor II in order to fix these proteins in a juxtaposition favor-
able for their interaction.
In this arbicle we report the importance of the 7-carboxy-Glu residues for the
interaction between the three clotting factors on the phospholipid by com-
paring PIVKA-II and factor II. These 1-carboxy-Glu residues are present in the
factors II and X", but they are absent in PIVKA-II. As a consequence the affin-
ity of PIVKA-II towards phospholipids is strongly reduced [9]. The behaviour of
PIVKA,II as a substrate in prothrombinase will therefore depend solely on pro-
tein-protein interactions in the enzyme ' substrate complex.
Materials and Methods
Buffers. Buffer A: 0.02 M Tris . HCl, pll7.2lO.1M NaCt/0.01 M benzamidi-
nium chloride. Buffer B: 0.02 M Tris'HCI, pH7.210.25 M NaCl/0.01M ben-
zamidinium chloride. Buffer C: 0.0286 M sodium barbital, pH 7.4/0.0286 M
sodium acetate/0.1164 M NaCl. Buffer D: 0.005 M phosphate buffer, pH 6.8/
0.1 M KCI/0.01 M benzamidinium chloride. Buffer E: 0.2 M phosphate buffer,
pH 6.8/0.1M KCI/0.01 M benzamidinium chloride.
Coagulation fesfs. Factor II activity was assayed with the one-stage coagula-
tion assay and PIVKA-II with the Echis Carinatus venom assay as described
before [10]. For the two-stage detection of thrombin in a system containing
purified clotting factors the bovine fibrinogen solution [10], which was devoid
of factors II, VII and X, was freed from residual factor V by repeated precipita-
tion with 2 M glycine'and subsequent dialysis against buffer C.
From reaction rnixtures in which thrombin was generated we took at various
incubation times 0.2-ml aliquots which were mixed with 0.2 ml of the fibri-
nogen solution (2 mg/ml) at 37" C. The time required for clot formation in
these samples was used to determine the amount of thrombin in the original
reaction mixtures by comparison with clotting times obtained with known con-
centrations of thrombin.
Normal pool plasma, definition of units. Bovine reference plasma was pre-
pared as described in ref. 10. The amount of each clotting factor present in this
plasma was arbitrarily taken LOOVo v 1 unit/ml. In a similar way LOOVo (1 unit/
ml) of PIVKA-II was defined as the amount of PIVKA-II which gives the same
clotting time in the E. Carinatus assay as plasma containing I007o of factor II.
Preparation of PIVKA-II concentrate. Normal healthy cows were anticoagu-
Iated with 500 mg of Marcoumar on the first day and 150 mg each following
day. At the fifth day 5 I of blood from each ibw were collected in oxalate and
the plasrna was separated from the blood cells by centrifugation for 20 min at
3000Xg. Normal clotting factors II,. VII and X were removed by AI(OH)3
adsorption (1.5 mg/ml) and PIVKA-X was removed by adsorption onto BaSOa
(50 mg/ml). Subsequently PIVKA-II was isolated from the plasma by batchwise
adsorption on QAE-Sephadex (20 ml slurr5r per I of plasma). After stirring for
t h the slur,ry was brought into a column (2.5 X 100 cm) and washed with buf-
fer A. PIVKA-II was eluted bv a frontal elution with buffer B. The concen-
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trated PIVKA-II was dialyzed against buffer A and frozen at -70"C or used
immediately for further experiments.
Snalze uenams. Echis carincfus venom and Russell's viper venom were ob-
tained from Sigma. The two components in Russell's viper venom which selec-
tively activate the factors V and X were separated as described by Schiffman et
al. [11]. The activating components will be referred to as venom-V and venom-
X, respectively.
Coagulation factors. Factor II was purified according to Owen et al. [12].
Factor V was purified according to Dombrose et al. [13] and factor X was puri-
fied according to Fujikawa et al. [14]. The factors V and X were activated with
venom-V and venom-X, respectively, by addition of 1 pg of venom per unit of
coagulation factor to an incubation mixture containing 20 mM CaClr,0.1 M
NaCI and 20 mM Tris . HCl, pH 7 .4. The incubation was ca.rried out for 5 min
at 37"C and the activated factors were subsequently separated from the venom
by Sephadex G-100 chromatography.
Phospholipids. A human brain phospholipid preparation was made according
to Bell and Alton [15]. The final concentration was 0.5 mg/ml.
Quantitatiue determination of y-carboxy-Glu residues in PIVKA-1L The
determination of 7-carboxy-Glu residues was performed according to a modi-
fied procedure of Zylkovicz and Nelsestuen [16]. This procedure which will be
presented in more detail elsewhere (Kop, J. and Hemker, H.C., unpublished
results) is based on acetylation of the protein preparation followed by reduc-
tion with l3Hldiborane. The reduction was accomplished while stirring the
solution at room temperature for 100 h. After this period of time the reduc-
tion was completed and subsequently amino acid analysis was performed on an
LKB amino acid analyzer Model 320L. The amino acids were separated at a
temperature of 30'C. Fractions of 0.8 mI were collected and counted. The
retention times for 5,5-dihydroxyleucine, homoserine, 5-hydroxynorvaline and
glutamic acid were 72,86,90 and 102 min, respectively. Homoserine and 5-
hydroxynorvaline are obtained after reduction of aspartic acid and glutamic
acid and are separated completely from the other amino acids. From the peak
height (absorbance) and the radioactivity (dpm) we calculated the specific
radioactivity, which is defined as dpm obtained when one amino acid per mole-
cule (PIVKA-II or factor II) is reduced. This is necessary because 5,5-dihy-
droxyleucine (obtained after reduction of 'the y-carboxy-Glu residues) did not
separate from other (unlabelled) amino acids. When the specific radioactivity
is known, the amount of 7-carboxy-Glu residues can easily be calculated from
the total dpm at the position of 5,5-dihydroxyleucine.
Labelling of PIVKA-II and factor.[/. Samples containing either PIVKA-II
alone or a mixture of PIVKA-II and factor II were labelled by reductive methy-
lation according to the method of Gualerzi et al. [17]. The reaction was per-
formed with 1-ml samples containing 2 mglml of protein. After dialysis against
borax.buffer (50 mM Na2BoOr, 200 mM KCl, pH 9.0), 0.02 mci [14C]formal-
dehyde (15 Ci/mol) was added and the mixture was incubated for 30 s in ice.
The reaction was repeated with 0.02 mci I4CH2O, followed by incubation for
45 s in ice. After addition of 2O 1tl NaBHq (2Vo in borax buffer), the reaction
mixture was dialyzed extensively against buffer A without benzidinium chlo-
ride. This procedure gives radiolabelled clotting factors without observable loss
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of clotting activity, with a specific activity of 2 ' 106 dpm/mq'
Potyaciylamide gel eleetrophoresis. Polyacrylamide gel electrophoresis was
accomplished in gels containing 
'I7o polyacrylamide in a buffer containing 5
mM iris . HCi, pH A.+, 88.4 mM glycine and 1.5 mM CaCl2 as initially
described by Davis [18].
Results
The pIVKA-II concentrate obtained as described in Materials and Methods
was applied to a QAE-sephadex column (1 x 30 cm) in buffer A. The column
*u, *Jrhud with the ."*L b.rff"r and eluted with a linear gradient (twice 250
ml) from buffer A to buffer B. The fractions were dialyzed against buffer A
wilhout benzamidinium chloride and assayed for PIVKA-II with the aid of the
E. Carinatus assay and for factor II with the one-stage coagulation assay (Fig'
1). In this way we obtained two peaks: a first one which was active in the E'
iarinatus assay but hardly in the one-stage coagglation assay, and a second
one eluting at a higher salt concentration, which was equally active in both
the E. Carinatus uttd thu coagulation assay. Since we were able to remove both
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activities from the latter peak by BaSOa adsorption, we concluded that these
fractions contained factor II.
On the contrary, the first peak did not adsorb onto BaSOa and we were con-
cerned with the question: is the factor II activity in our PIVKA-II preparation
due to a contamination of PIVKA-II with thrombin or prothrombin or does
PIVKA-II exhibit a one-stage factor II activity on its own?
The presence of thrombin could be excluded because: (a) in the absence of
CaCl2 no clotting was observed; (b) before and after SP-Sephadex chromatog-
raphy the clotting times remained unchanged (as reported by Esmon et al. [19]
SP-Sephadex removes any thrombin present in factor II or PIVKA-II prepara-
tions); and (c) addition of 10 mM of the thrombin inhibitor diisopropylfluoro-
phosphate and subsequent dialysis against buffer C did not prolong the clotting
time.
It turned out to be more difficult to exclude the possibility that small
amounts of prothrombin contaminated our PIVKA-II preparation. Therefore,
we purified PMA-II to homogeneity and analyzed it with the aid of physico-
chemical, chemical and kinetic techniques. This is reported in some detail (sub
A, B and C), because only when it is assured that no trace amounts of pro-
thrombin contaminated our PIVKA-II preparation, legitimate conclusions can
be drawn about the r6le of 7-carboxy-Glu residues in the action of prothrombi-
nase (sub D).
(A) The purification of PIVKA-II and the physicochemical determination of
contaminating prothromb in
PIVKA-II was further purified according to a slightly modified procedure of
Stenflo and Ganrot [20]. The fractions of the first peak shown in Fig. L con-
taining PIVKA-II and only very few factor II activity were pooled and dialyzed
against buffer A. The solution was subsequently adsorbed three times with
BaSOa (100 mg/ml). After each adsorption step the solution was centrifuged
for 5 min at 3000 X g and finally the supernatant was centrifuged f.or 20 min at
20 000 X g and further purified on DEAE-Sephadex, gradient elution from buf-
fer A to buffer B, hydroxyapatite, gradient elutron from buffer D to buffer E,
Sephadex G-150 and Sephadex G-100, both in buffer A. The latter column was
recycled once before the fractions were collected. The benzamidinium chloride
was removed by dialysis and the preparation was concentrated to 400Vo and
filtered through an SP-Sephadex column in buffer A without benzamidinium
chloride. This procedure yields PIVKA-II which is homogeneous when assayed
in polyacrylamide gels with or without CaClr in the presence or absence of
sodium dodecyl sulfate (SDS) and in bidimensional immunoelectrophoresis. The
amino acid composition was equal to that found by Magnusson et al. [21] to
within 37o. This PIVKA-II preparation we used for all experiments described
below and was called purified PIVKA-II.
In order to find out what is the lowest amount of factor II which is detect-
able in PIVKA-II we added small amounts of factor II to our PIVKA-II prepara-
tion and examined these mixtures with the aid of several physicochemical tech-
niques. The conventional way of separating PIVKA-II and factor II is crossed
immunoelectrophoresis [20]. Less than 5% of. factor II (w/w) could not be
detected in PIVKA-II, however. A better resolution was obtained with poly-
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acrylamide gel electrophoresis in the plesence of 1.5 mM caclz 
(see Materials
and Methods). Factor if urra PIVKA-II are completely separated with 
this tech-
nique (nig. d). Radiolabelling the samples with ll4c]formaldehyde 
prior to
electrophoresis and subsequent slicing and counting the gels appealed 
to be- !h9
most sensitive method for protein detection. Amounts of.0.57o 
(w/w) of added
prothrombin could n" uurii' detected in this way' No prothrombin was 
found
in our PIVKA-II preparation, however'
(B) Chemical d,etermination of contaminating prothrombiy -ilt PMA-II
With the metnoa initiatly ilevelopea uy zyttovicz and Nelsestuen [16] 
and
modified in our laboratory (see Matlrials and Methods) it was 
possible to quan-
titate the amount of 1-carboxy-Glu residues in prothrombin' 
In mixtures con-
taining prothrombin and PMA-II a mean value of the amount 
of 7-carboxy-
Glu residue, p"r -oi""rri" was obtained, e.g. a contamination of 
107o prothrom-
bin in pIVKA-II gave one residue per irolecule (prothrombin 
contains 10
residues per molecule). Analysis of oul purified PivKAIi 
preparation revealed
that less than 0.0b t"Jia"" pJr molecule was present (0.05 residue 
per molecule
was the lower limit of detection). This means that also with 
this method the
contamination of PIVKA-II with prothrombin is estimated 
to be less thart 0''vo'
(C) Kinetic ettid'ence for the absence of factor II in PIVKA-II
Purified PIVKA-II and factor II were tested at various dilutions 
with the one-
stage coagulation 
";;;;;"4 
with the E. Carinatus assay. When we plot the one-
stage clotting time (t") against the reciprocal concentration 
of PIVKA-II and
factor II, straight tines arelftained (Fig. 3). As describedLcy 
Hemker et al' [23'
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Fig: 3. f vs. D plot of purified factor II and purified PMA-IL The clottrng trmes ot lactor II (o---=------{)
and PIVKA-II (X-X) were clotting against the reciprocal substrate concentration. The clotting times
were obdained with the one-stage coagulation dssay. The concentration of PIVKA-II was assessed with the
Echis Carinatus assay.
tion time, f-1,,, (proportional to the inverse of ma:rimal clotting velocity V) arc
calculated. The values for factor II were K^= 3.37o &nd f6io = 15 s. For
PIVKA-II they were KI^= 25.4Vo and t;in = 75 s.
If the one-stage clotting activity of our PIVKA-II prepaxation is caused,,by
contaminating prothrombin only, the different K^ can be readily explained.
A contamination of (3.3/25.4)Y.LO0Vo=L37o (w/w) of prothrombin would
bring about this effect. T[ris amount of prothrombin would,,be detected easily
with our chemical and phys[cochemical techniques. Moreo-ver, when this was
the case, evidently f6i1 would not differ. Because f,oi,, does differ we have to
assume that either some modificator of factor II activity is present in the prepa-
ration or that PIVKA-II itself is a substrate in the one-stage factor II assay (see
also Discussion).
Several data argue against the first possibility, namely tha!.our PIVKA-II
preparation contains both factor II and a factor II inhibitor. Firstly, the amino
acid composition of PIVKA-II was found to be similar to that of purified factor
II. An inhibitor in PIVKA-II would be detected because the total amino acid
composition would differ from that of factor II. Secondly, the ratio between
the activities in the one-stage clotting assay and tt,e E" Carinatus assay. remained
constant at all stages of the purification of PIVKA-II. Also the K* ond f6ia
values remained constant (Table I). Even when the purified preparation was
adsorbed with excessive amounts of BaSOa, which is known to be a highly
selective absorbent for factor II, the K- and f-i' did not change, even when
967o of. PIVKA-II had been adsorbed from the solution. This can be explained
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TABI,E I
The K- and f*i, PMA-II at various stages of its purification. The staxting plasma contained approx.
5O7o of PIVKA-II. For turthe: details see text.
Purification step Recovery
(vo)
Purification Km tmin
(fold) (%) (s)
1 Plasma
2 QAE-sephadex frontal elution
3 QAE-Sephadex gradient elution
4 BaSO4 adsorption
5 DEAE-Sephadex gradient elution
6 Hydroxyapatite gradient elution
? Sephadex G-150
8 Sephadex G-1O0
9 SP-Sephadex
100
81
7.2
6 8
49
32
25
1 8
1 6
1
29
I
51
99
231
424
543
D C I
n.m.
26.5
25.4
27.3
24.8
24.2
27 .L
24.9
25.4
n.m.
7L
74
76
72
l e
73
t e
l c
n.m., not meazured.
in terms of contamination only if the ratio PlVKA-Il/prothrombin/inhibitor
remained constant during all these operations. thi's is' without doubt, highly
improbable. It is more likely, therefore, that PIVKA-II itself has some factor II
activity with kinetic palameters which differ from those of prothrombin.
As in the physicochemical and chemical techniques, the lower limit of detec-
tion of factor II in a PIVKA-II preparation can be determined by kinetic means
by measuring the effect of smali amounts of added prothrombin on the clotting
time, the K- and f-s, values.
As shown by Hemker et at. 122-241 the coagulation reactions of clotting
factors obey the rules of general enzyme kinetics, so we may express the reac-
tion velocity u(= tlt.) as follows:
y = Jl4l: (1)'  
K m + [ S ]
in which [S] is the substrate concentration (factor II or PMA-II). Y"l .,
arld V are expressed as the leciprocal clotting time (t") and the reciprocal mini-
mal clotting iime (t*,) and the observed values axe substituted in Eqn. 1 we
obtain for factor II:
1/ f* i ,  .  [F I I ]
u = Lltc = Z* +1F tt1- 
=
and for PIVKA-II:
0.067 [F rr]
SSFIFrIT (2)
Lltln" IPTVKA-rI] (3)ul -= 1lf6 = Kl, + [PIVKA-II]
When factor II and PIVKA-II are both present in the same reaction mixtures'
the rate of thrombin generation may be thought to be the sum of the individual
reaction rates. From Eqns. 2 and 3 we get:
V t o t a r = V t V *
0.013 [PrVKA-II]
25.4 + [PTVKA-II]
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so
1tr = 1tt. + 1tt! = 0.067 [F II] * 0.91914r8A-lIILrzc Ltoc '  Ltuc 
TT+lFlIT 
'
25.[+ lptVrA-tr f l
(4)
l
in which ?" is the observed clotting time.
When known amounts of PIVKA-II and factor II are mixed, the clotting time
can be calculated with Eqn. 4 and compared with the observed clotting time.
The results of this kind of experiment are shown in Fig. 4, in which we made
dilution curves from mixtures containing 400vo of PIVKA-II and either 0.5,2
or 57o of factor II. It is clear that the calculated and observed clotting times are
in close agreement and that neither the observed not the calculated lines are
linear. Only the curves of purified PIVKA-II and factor II are rectilinear.
When factor II would cause the one-stage coagulation activity of PIVKA-II,
the addition of more factor II would given again, a straight line. However, the
observed lines are curved. This means that by mixing of PIVKA-II and factor II
we bring together two different substrates with different kinetic parameters. In
. other words, PIVKA-II has one-stage clotting activity of its own. The curvature
of the clotting time versus dilution plot is obvious even in the case of very low
amounts contaminating factor II (0.12570, w/w). Thus the kinetic method is
the most sensitive way of detecting small amounts of factor II in PIVKA-II and,
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Fig.4. f vs. D plots of mixtures containing purif ied PIVKA-II and purif ied factor II. with the aid of the
known values of the .tr(- and f-1o of PIVKA-II and factor II the clotting times of these mixtures were ca-l-
culated (see text). The foltowing samples were examined: *-*, 4 units/ml of pIVKA-II; .---o, 4
units/ml of PIVKA-II, containing O.125?o (w/w) of factor II i *-r, 4 units/ml of pIVKA-II. contain-
ing O.6Vo (wiw) of factor II; *--ni 4 units/ml of PIVKA-II, containing I.2bVo (wlw) of factor II;
4---r, 4 units/ml of factor II. In the case of the mixtures the solid line is the calculated curve and the
markings r.epresent the observed values.
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TABLE II
The K- and V of PIVKA-II after BaSO4 adsorption. 3 ml of purif ied PIVKA-II were supplemented with
BaSOa and shaken on a Vortex mixer fot 2 min. After centrifugation for 2O min at 20 000 X g the
PIVKA-II concentration was measured by the E. Carinatus assay. Similar mounts of purif ied factor II
were adsorbed completely bv less than 2 mglml of BaSO4.
BaSO4 added
(mg/ml)
PIVKA-II (7o) Km
E- Carinatus assay (Vo)
rmin
(s )
t c
71,
74
25.4
26 .8
24.9
o
20
40
1 1 5
1.1
4 .5
moreover, it gives the direct proof that PIVKA-II is active in the one-stage
coagulation assay.
(D) The react ion mechanism of thrombin generat ion from PMA-II
Once we knew that out PIVKA-II preparation did not contain factor II or
thrombin, we were interested in the question of how is PIVKA-II converted
into thrombin in the one-stage coagulation assay? In other words: can the ples-
ence of only factor X" explain the conversion of PIVKA-II oI ale other com-
ponents (factor V, phosphotipid) required in this reaction? We therefore modi-
fied our one-stage coagplation assay in such a way that the factors VII and X
were replaced * by factor X" while thromboplastin was replaced by phospho-
Iipids. In this system the ciotting time versus dilution plot for PIVKA-II was
almost similar to that shown in Fig. 3. However, in the absence of phospho-
lipids very long clotting times wele obtained, even when an excess of factor Xu
(700OVo) was present. Therefore we repeated and extended some experiments
of Esmon et al. [3,9] and measured the rate of thrombin genelation from puri-
fied factor II and pudfied PIVKA-II with a two-stage method (see Materials and
Methods). Equal amounts of either factor II or PIVKA-II were incubated with:
a, factor X. and CaCl2; b, factor Xu, phospholipids and CaCl2;c, factor Xu, fac-
tor V, and CaCl2; d, factor X., factor Vu, phospholipids and CaCI2.
The last expeliment, which gave an unexpected result, has not been carried
out by Esmon et al. The results are summarized in Table III. It is clear that fac-
tor Xu is able to generate thrornbin from factor II and PIVKA-II at the same
rate. Addition of phospholipids in the absence of factor Vu causes an increase
of the thrombin generation from factor II and does not influeuce that from
PIVKA-II (entries a and b). In the presence of factor Vu, hortever. the addition
of phospholipids does influence the thrombin generatiotr from PIVKA-II
although not to the same extent as .irat from factor II (entries c and d)' We
repeatedly found at least a lO-fold stimulation by phospholipids of the throm-
bin generation from PIVKA-II in the presence of factor \ru. Onll- the clotting
times which were obtained for PIVKA-II in the presence of phospholipids and
factor Vu were in good agreement with those obtained in the one-stage coagula-
tion assay.
* The factors VII and X were removed bv BaSO+ adsorption and a small vohme of highly concen-
trated (6000 units/ml) factor Xa was added to the reagent.
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TABLE III
The rate of thrombin formation from factor II and PIVKA-II in different activation mixtures. Factor II
(6ovo) or PIVKA-II (\ovo) were incubated at 37oc with different combinations of activators, The incuba-
tions were carried out in reaction mixtures containing 2o mM Tris . HCl, pH ?.4. g mM cacb and 0,1 M
NaCl. The concentrations of other components (if added) were: factor x^, L4vo: faciror Vl, L4voi and.
phospholipids, 5O pglml. The activation rate is given in N.I.H. units of thrombin formed per min per ml.
The relative rate of entry a was arbitrarily chosen to be l.
Activators Factor II
Activation rate Relative rate
PIVKA.II
Activation rate Relative rate
(a) Xu, Ca*
(b) Xa, Caz+, PL
(c) Xa, Caft, Va
(d) Xa, ca2t, Va, pL
o.o4
o.o4
1 . O
t 2
Discussion
_ PIVr(A-II preparations always show thrombin generation in a one-stage pro-
thrombin assay. The clotting time obtained cann;t be explained solely bythe
action of factor Xu in solution. Therefore, we wish to prove that the generation
of thrombin from PIVKA-II by factor Xu is accelerated by phospholipids and
factor V. This phenomenon is shown in ihe experiments rlported in Table III.
A trivial explanation for these observations would be that our pIVKA-II prepa_
ration contains about 37o of prothrombin. The following evidence can be pre-
sented to exclude this possibility.
(a) Physicochemical euidence. Gel electrophoresis in the presence of 1.5 mM
cacl, separated PIVKA-II from factor II and showed that our PIVKA-II prepa-
ration contained less then 0.b%o f factor II.
(b) Chemical euidence. N-Terminal analysis and overall amino acid analysis
of PIVKA-II and factor II gives identical results. Specific determination oi 7-COOH glutamic acid residues by reduction with radioactive diborane (see Mate-
rials and Methods) in our hands would demonstrate less than 0.0b 7-.*6o*n-Glu residue per molecule, i.e. less than 0.Evo prothrombin in a preparation con-
taining 100vo of PIVKA-II. However, none was found. Moreover, this result
shows that the PIVKA-II molecules itself are also devoid of 7-carboxy-Gluresidues.
(c) Kinetic euidence. The plot of clotting times against the reciprocal pro-
thrombin concentration (f vs. D plot) has been demonstrated to be a straight
line. From Fig. 3 it can be seen that both prothrombin and PIVKA-II giv! a
straight line. If our PIVKA-II preparation consisted of an inert protein lrlVra-il) mked vmth cvo of prothrombin, the rine obtained with prothrombin and
that obtained with PIVKA-II would only differ uppurerrlly because the-
clotting time obtained with p7o of PIVKA-IIis entered ai a point at the abcissa
corresponding to l/p whereas it should be entered at 1,00lcxrlp. The effect
would obviously be that the pIVKA-II line is the prothro-tin linl represented
with an abcissa which is oshrunk'by a factor 10ol;. The intercept with the ordi_
nate would remain the same, but the intercept with the abcissa would be
shifted right by the factor clL}o, i.e. f-1, would be identical to f|1, 
""Jtrr"
o.o4
o.3
4.O
440
I
l . o
100
11  000
1
1
2 5
300
I
j
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K| should be 100/c X K-. From Fig. 3 it is seen that (a) f-i, is not identical
and (b) Ki, = 8 K-. As is argued above, (a) cannot be explained by contamina-
tion and (b) would be explained only by a 72.5% contamination of factor II in
PIVKA-II. These amounts of prothrombin would have been readily detected by
our chemical and physicochemical methods.
A theoretical possibility remains that our PIVKA-II preparation contains
both normal prcthrombin and a competitive inhibitor of normal prothrombin
conversion and that this would explain our results. Three reasons argue against
this explanation: (1) It would not explain the curved t vs. D plots upon mixing
prothrombin and PIVKA-II (Fig. a). (2) Adsorption onto BaSOa (as well as the
PIVKA-II purification procedure) would shift the ratio prothrombin/inhibitor
and thereby cause other apparent K* and f-i, values. It does not in the actual
experiment. (3) The overall amino acid composition of PIVKA-II is similar to
that found by Magnusson et al. [21] for factor II. A competitive inhibitor
would change the amino acid composition.
It is possible to calculate the combined effect of prothrombin in a PIVKA-II
preparation on basis of the f-i, 6d K- read from Fig. 3. In general this will
result in curved t vs. D plots. The curvature of these plots is obvious even when
factor II is present in FIVKA-II at a ratio of 1 : 800 (Fig. 4).
If the one-stage coagulation activity of PIVKA-II were due to the presence of
contaminating factor II, straight lines with coinciding f-r, would be expected
upon addition of more factor II. The fact that we observed curved lines thus
proves that PIVKA-II itself has clotting activity in the one-stage coagulation
assay.
This conclusion is important for the interpretation of the results shown in
Table III. In this table we show that in the absence of factor Vu the thrombin
generation from PIVKA-II by factor Xu is not accelerated by the addition of
phospholipids. On the contrary, in the presence of factor Vu, phospholipids
stimulate this thrombin generation about 1O-fold.
The only way to interpret these results is by assuming that by its affinity to
factor V., PIVKA-II is able to bind indirectly to phospholipids, thus becoming
more accessible to the proteolytic activity of factor Xu. Because Ca2* were
required for effective action of factor Xu, we were not able to investigate
whLther factor V" needs Ca2* in its bridging function between phospholipids
and PIVKA-II.
Between factor II and PIVKA-II there are no differences in the fragment-2
region, which is the factor v,-binding part l2,gl.Therefore we may expect that
also during the conversion of prothrombin into thrombitr, factor V* binds to
prothrombln and that this binding is essential for the accelerating effect of fac-
lor V in this reaction. This indicate. Lnat factor II is bound to the phospho-
lipids in two ways: directty via y-carboxy-Glu residues and indirectly via factor
V.. as is shown in Table III, there is a difference (about 4-fold) between the
raie of thrombin generation from PIVKA-II and factor II in the presence of
only the factors V" and Xu. This is a variance with the results of Esmon et al'
[9]. We cannot offer an explanation at this moment. Possible explanations are
(uf ttu"" amounts of phospholipid in our factor V preparation, but not in
Esmon's; (b) trace amounts of prothrombin in Esmon's PIVKA-II preparation;
(c) differences due to slightly different experimental conditions (e.g' concentra-
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tion of enzyme, substrate, etc.). We consistently found this difference, even in
experiments in which we approached Esmon's conditions as closely as possible,
and this renders explanation c less likely.
In order to find out whether also factor X" has some affinity to factor vu,
the experiments of Table III should be repeated with reaction mixtures cori,
taining factor rr, c*_* and PIVKA-X. or factor X", whether or not supple-
mented with factor vu, phospholipid or a combination thereof. up to now,
however, experiments of this kind have been hampered by the fact that it is
very hard to prove that a PIVKA-X preparation does not contain trace amounts
of factor X.
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